Document is current
Any future updates will be listed below
-
Authors
Du, Ping
Tao, Xuelian
Harati, Javad
Shi, Yue
Xiao, Liang
Li, Xian
Pan, Haobo
Wang, Peng-Yuan https://orcid.org/0000-0001-7965-2914
-
Funding
Funding for this research was provided by:
Ministry of Science and Technology of the People’s Republic of China (2022YFA1105101)
Natural Science Foundation of Zhejiang Province (LZ23C070004)
Shenzhen Science and Technology Innovation Program (JCYJ20220531095811027)
- License Information
-
More Information
Article History
Received: 25 June 2024
Accepted: 28 November 2024
First Online: 18 December 2024
Declarations
:
: This was not a clinical trial, so consent to participate was not applicable, nor was the declaration of Helsinki for ethical principles for medical research involving human subjects. Human fetal bone marrow mesenchymal stem cells (BMSCs; HUXMF-01001; ) and human adipose-MSCs (ASCs; HUXMD-01001; ), as well as the medium, were purchased from Cyagen Biosciences (Guangzhou) Inc. These two human cell lines have been published by our group ( and ). Human platelet lysate was purchased from Helios BioScience (HPCFDCRL10; UltraGROTM Advanced; ). This product has been published by our group (). The Shenzhen Institute of Advanced Technology (SIAT) ethics department, Chinese Academy of Sciences (CAS), has no objection to the human cell lines and medium purchased in this study.
: Not applicable.
: The authors declare that they have no competing interests.
